Reparixin (Repertaxin, DF 1681Y)，又称瑞帕利辛，是非竞争性的CXCL8趋化因子受体CXCR1/2的变构抑制剂，IC₅₀值为1 nM和100 nM，具有抗炎及潜在的抗癌活性。Reparixin临床上已用于预防缺血再灌注损伤和炎症，并且处于治疗三阴性乳腺癌的临床试验中。

参考文献

1. Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.
2. Kim HY, et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34(1):120-7.
3. Zarbock A, et al. Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice. Br J Pharmacol. 2008 Oct;155(3):357-64.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。